Stocksigma LogoStocksigma Logo

ZIM Laboratories Q2 FY27 Earnings Presentation

ZIM Laboratories reported total operating income of ₹1,054 Mn in Q2 FY27, up 18.9% YoY and 12.0% QoQ, led by RoW formulations

ZIM Laboratories Q2 FY27 Earnings Presentation

Zim Laboratories Ltd · Investor Presentation · 05 Nov 2026, 2:11 am

ZIM Laboratories Q2 FY27 Earnings Presentation ZIM Laboratories reported total operating income of ₹1,054 Mn in Q2 FY27, up 18.9% YoY and 12.0% QoQ, led by RoW formulations. Export revenue grew 24.7% YoY to ₹908 Mn, representing 86% of sales. EBITDA stood at ₹77 Mn with margins at 7.3% (-149 bps YoY), compressed by developed-market readiness costs and EU-GMP CAPA remediation expenses (~₹180 Mn over 15 months). Net loss was ₹21 Mn due to higher depreciation and finance costs. Australia TGA GMP approval was secured, while EU-GMP re-certification remains on track.

Original exchange filing (PDF)

More announcements from Zim Laboratories Ltd

All Zim Laboratories Ltd announcements